Our recent data implicated IL-1α as the key IL-1 agonist driving cerebrovascular inflammation [ 16].
The key IL-6 positive action is its relationship with physical activity via enhancement of insulin-stimulated glucose disposal in humans in vivo [ 64, 70].
Recent studies further identified type 2 innate lymphoid cells as the key IL-25-responsive cells that produce IL-5 and IL-13, major downstream effector molecules of IL-25 in promotion of type 2 immunity [ 27].
Furthermore, we are presently investigating the expression of the two key IL-17 receptor chains on breast cancer cells, RA and RC, which heterodimerise to mediate signalling following binding of IL-17A and IL-17F.
For example, in Th1 cells, MAF and SMAD4 are key IL-10 transcription factors; however, in Th2 cells, GATA3, Jun, and MAF are specific transcription factors for IL-10 expression, while STAT3 or STAT1 are the important factors for IL10 in Th17 expression [ 11- 14].
Using an in vitro macrophage cell culture system we then tested for possible effects of gas vesicle uptake on cytokines produced by cultured macrophages through quantification of three (3) key examples: IL-10, IL-12 and IL-18.
Thus far, most studies have speculated about a possible role for Th17 cells, i.e. CD4 T cells which, in addition to key cytokine IL-17A, also have been described to be able to produce IL-22.
Moreover, transcripts of genes encoding the key cytokine IL-15 and the chemokine CCL5 were normal in δD910A mice.
A similar offspring phenotype can result from administration of key inflammatory (IL-6 and TNF-α) or anti-inflammatory (dexamethasone) mediators during midgestation [ 23].
These pathways may be active in patients who are refractory to biologic therapies that target key cytokines, IL-1 and tumor necrosis factor alpha.
